Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• The COVID-19 pandemic highlighted the vulnerability of patients with Multiple Sclerosis (MS) undergoing immunosuppressive therapies.
• Mass vaccination campaigns raise questions about the safety and efficacy of vaccines in immunocompromised populations, including MS patients on cladribine tablets (Mavenclad).
• Existing data on vaccination in MS patients treated with cladribine is limited, necessitating a review of available evidence.

Purpose of the Study:

• To evaluate the safety and efficacy of vaccine administration in Multiple Sclerosis patients treated with cladribine tablets.
• To determine optimal timing for vaccination in relation to cladribine treatment cycles.
• To review existing literature and preliminary data on immune responses to various vaccines (influenza, VZV, SARS-CoV-2) in cladribine-treated MS patients.

Main Methods:

• Literature review of existing studies on vaccinations in MS patients.
• Analysis of pharmacokinetic/pharmacodynamic data of cladribine.
• Examination of immune system changes post-cladribine administration and preliminary humoral response data to influenza, VZV, and SARS-CoV-2 vaccines.

Main Results:

• Cladribine tablets appear to offer flexibility in vaccine administration timing.
• Preliminary data suggests that vaccination in cladribine-treated MS patients is likely safe and effective.
• Understanding cladribine's mechanism of action and its impact on the immune system supports vaccine feasibility.

Conclusions:

• Vaccination of Multiple Sclerosis patients treated with cladribine tablets is suggested to be safe and effective.
• The timing of vaccination can be flexible, accommodating cladribine treatment schedules.
• Further research and empirical data are encouraged to solidify these findings for MS patient vaccination strategies.